Cellectar Biosciences Inc Share Price Nasdaq
Equities
US15117F3029
Pharmaceuticals
Sales 2024 * | - | Sales 2025 * | 44.27M 3.54B | Capitalization | 97.75M 7.83B |
---|---|---|---|---|---|
Net income 2024 * | -49M -3.92B | Net income 2025 * | -22M -1.76B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.21 x |
P/E ratio 2024 * |
-1.86
x | P/E ratio 2025 * |
-5.25
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.18% |
Latest transcript on Cellectar Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
James V. Caruso
CEO | Chief Executive Officer | 65 | 14/06/15 |
Chad J. Kolean
DFI | Director of Finance/CFO | 59 | 27/05/14 |
Andrei Shustov
CTO | Chief Tech/Sci/R&D Officer | - | 14/02/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 06/04/17 |
Douglas Swirsky
CHM | Chairman | 54 | 06/04/17 |
John Neis
BRD | Director/Board Member | 68 | 31/01/08 |
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |